Table 1.
The expression of UCHL5 was correlated with demographic and clinical pathological characteristics in patients with NSCLC (LUAD and LUSC)
| LUAD UCHL5 | LUSC UCHL5 | ||||||
|---|---|---|---|---|---|---|---|
| high | low | p value | high | low | p value | ||
| Age | |||||||
| ≥60 | 175 | 180 | 0.666 | 196 | 205 | 0.296 | |
| <60 | 70 | 66 | 50 | 41 | |||
| Sex | |||||||
| Male | 129 | 107 | 0.051 | 192 | 179 | 0.212 | |
| Female | 126 | 148 | 59 | 71 | |||
| Tabaco smoking history | |||||||
| Stage 3-5 | 161 | 143 | 0.097 | 166 | 172 | 0.513 | |
| Stage 1-2 | 87 | 105 | 79 | 72 | |||
| Other malignancy history | |||||||
| Negative | 242 | 228 | 0.031* | 218 | 215 | 0.694 | |
| Positive | 13 | 27 | 32 | 35 | |||
| Laterality | |||||||
| Left | 92 | 107 | 0.120 | 114 | 99 | 0.165 | |
| Right | 155 | 141 | 122 | 137 | |||
| Location of lung parenchyma | |||||||
| Peripheral lung | 60 | 65 | 0.440 | 47 | 46 | 0.895 | |
| Central lung | 34 | 29 | 73 | 74 | |||
| Residual tumors | |||||||
| Negative (R0) | 170 | 171 | 0.991 | 199 | 199 | 1.000 | |
| Positive (R1/R2) | 8 | 8 | 8 | 8 | |||
| Tumor size | |||||||
| T1 | 66 | 101 | 0.001* | 50 | 64 | 0.142 | |
| T2-T4 | 187 | 153 | 200 | 187 | |||
| Lymph Node Stage | |||||||
| Negative | 151 | 177 | 0.017* | 155 | 164 | 0.433 | |
| Positive | 98 | 73 | 92 | 84 | |||
| Distant metastasis | |||||||
| Negative | 167 | 174 | 0.147 | 204 | 207 | 0.253 | |
| Positive | 16 | 9 | 5 | 2 | |||
| Tumor Stage | |||||||
| Ⅰ/Ⅱ | 188 | 205 | 0.040* | 201 | 205 | 0.617 | |
| III/IV | 63 | 46 | 48 | 43 | |||
The clinical information from the patients with NSCLC (510 patients with LUAD and 501 with LUSC) was retrieved from the cBioportal for Cancer Genomics (TCGA) databases for correlation analysis. NSCLC: non-small cell lung carcinoma; LUAD: lung adenocarcinoma; LUSC: lung squamous cell carcinoma. *p<0.05 was considered significant.